.infobox .infobox-protein
!!! Info
- Protein Name: Platelet-Derived Growth Factor Receptor Beta (PDGFR-Beta)
- Gene: PDGFRB
- UniProt: P09619
- Receptor Class: Receptor tyrosine kinase (RTK)
- Primary Ligands: PDGF-B Protein, PDGF-AB, PDGF-DD
- Functional Axis: Pericyte maintenance, BBB integrity, neurovascular signaling
PDGFR-beta (PDGFRB) is a receptor tyrosine kinase that translates platelet-derived growth-factor ligands into pericyte survival, vascular maturation, and neurovascular homeostasis programs.[1][2] In the adult CNS, PDGFRB expression is highly enriched in mural-cell lineages, making it one of the most biologically specific molecular handles for pericyte status in neurodegeneration studies.[3][4] This receptor has become central to Alzheimer's and vascular-neurodegeneration research because blood-brain barrier failure and capillary dysfunction are now recognized as early contributors to cognitive decline.[5][6]
PDGFRB is a single-pass transmembrane RTK with extracellular Ig-like ligand-binding domains and an intracellular split kinase domain.[1:1] Ligand binding induces receptor dimerization and autophosphorylation, then engages canonical pathways including PI3K-AKT, RAS-MAPK, PLC-gamma, SRC-family signaling, and cytoskeletal remodeling cascades.[2:1]
In brain vascular units, this signaling logic supports:
Disruption of PDGF-B/PDGFRB signaling in model systems causes severe pericyte deficits and BBB malformation, establishing this axis as non-redundant for cerebrovascular integrity.[3:2]
In mature brain, reduced pericyte function and impaired PDGFRB signaling are associated with leakage, inflammatory entry, and impaired clearance environments that can intensify proteinopathy-related toxicity.[4:2][5:1]
Soluble/CSF PDGFRB measures are widely used as pericyte-injury surrogates in translational studies. While assay harmonization remains an issue, PDGFRB-linked markers are increasingly integrated with imaging and fluid biomarker panels in early cognitive decline research.[5:2][7]
Human data show BBB breakdown can precede overt dementia symptoms, and APOE4 carriers display stronger neurovascular vulnerability signatures.[5:3][6:1] PDGFRB sits at the center of this biology through its pericyte dependence, making it a mechanistically grounded target for vascular-first intervention strategies.
Although direct PDGFRB-targeted trials in PD/PSP/CBS are limited, the pathway intersects with disease-relevant mechanisms including capillary dysfunction, metabolic stress, and neuroinflammatory amplification. PDGF-BB translational efforts in PD reinforce feasibility of pathway-level modulation.[8][9]
Pathogenic PDGFRB variants are linked to primary familial brain calcification and related movement/cognitive syndromes, highlighting that receptor dysfunction can itself produce progressive CNS pathology.[10][11]
The dominant neurodegeneration hypothesis is to restore pericyte-neurovascular resilience rather than drive strong proliferative signaling. This requires carefully titrated pathway support, not maximal receptor stimulation.[2:2][9:1]
In practical terms, most clinical-forward approaches currently modulate the axis through ligands (for example PDGF-BB) or downstream vascular-protective programs, with PDGFRB engagement assessed via biomarker panels.[8:1][9:2]
In oncology and fibrotic disease, PDGFRB inhibition is common; in neurodegeneration this is usually undesirable unless there is a distinct proliferative pathology. Translational protocol design must explicitly separate these contexts.[1:2]
Because PDGFRB regulates proliferative and vascular remodeling programs, neurodegeneration trials should include:
Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes & Development. 2008. ↩︎ ↩︎ ↩︎
Tallquist M, Kazlauskas A. PDGF signaling in cells and mice. Cytokine & Growth Factor Reviews. 2004. ↩︎ ↩︎ ↩︎
Bell RD, Winkler EA, Sagare AP, et al. Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature. 2010. ↩︎ ↩︎ ↩︎
Bell RD, Winkler EA, Singh I, et al. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron. 2010. ↩︎ ↩︎ ↩︎
Nation DA, Sweeney MD, Montagne A, et al. Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nature Medicine. 2019. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Bell RD, Winkler EA, Singh I, et al. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature. 2020. ↩︎ ↩︎
Sweeney MD, Sagare AP, Zlokovic BV. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nature Reviews Neurology. 2018. ↩︎
Paul G, Zachrisson O, Varrone A, et al. Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson's disease patients. Journal of Clinical Investigation. 2015. ↩︎ ↩︎ ↩︎
Su EJ, Fredriksson L, Schielke GP, et al. Pharmacological targeting of the PDGF-CC signaling pathway for blood-brain barrier restoration in neurological disorders. Trends in Pharmacological Sciences. 2016. ↩︎ ↩︎ ↩︎
Nicolas G, Pottier C, Maltête D, et al. Idiopathic basal ganglia calcification-associated PDGFRB mutations impair the receptor signalling. Molecular Psychiatry. 2013. ↩︎
Keller A, Westenberger A, Sobrido MJ, et al. PDGF, pericytes and the pathogenesis of idiopathic basal ganglia calcification (IBGC). Brain Pathology. 2013. ↩︎